StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a research report sent to investors on Wednesday morning. The firm issued a hold rating on the stock.
Separately, JMP Securities reiterated a "market outperform" rating and set a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.
Get Our Latest Report on DBVT
DBV Technologies Trading Up 6.0 %
Shares of NASDAQ DBVT traded up $0.25 during mid-day trading on Wednesday, reaching $4.45. The company had a trading volume of 14,836 shares, compared to its average volume of 82,473. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.09. The stock has a market cap of $91.53 million, a PE ratio of -0.99 and a beta of 0.67. The company has a 50-day moving average price of $4.11 and a two-hundred day moving average price of $3.83.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
